Baxalta
| Company type | Subsidiary |
|---|---|
| NYSE: BXLT | |
| Industry | Biotechnology |
| Founded | 2015 (Spun off from Baxter International) |
| Fate | Acquired by Shire |
| Headquarters | United States |
Key people | Ludwig N. Hantson (president and CEO) |
| Products | Hematology, Immunology, Pulmonology |
Number of employees | 16,000 |
| Parent | Takeda Pharmaceutical Company |
| Website | www |
Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. The company began its operation with a revenue of $6 billion, and is now a subsidiary of Takeda Pharmaceutical Company.